Advertisement

La preservazione della fertilità nel tumore del testicolo

  • Andrea GarollaEmail author
  • Andrea Canossa
  • Marco Ghezzi
  • Carlo Foresta
Rassegna
  • 1 Downloads

Sommario

Un effetto collaterale che si associa alle terapie per il trattamento del tumore al testicolo è rappresentato dalla perdita della fertilità. Prima delle cure è importante affrontare l’argomento e informare il paziente sull’opportunità di preservare la fertilità. La possibilità offerta per ovviare a questo problema è quella di crioconservare gli spermatozoi. In seguito, se il potenziale di fertilità fosse idoneo, sarà possibile l’utilizzo del campione per un ciclo di Procreazione Medicalmente Assistita (PMA), rendendo possibile la paternità anche a pazienti che dopo la terapia adiuvante sono diventati sterili.

Parole chiave

Tumore al testicolo Infertilità Crioconservazione Spermatozoi PMA 

Notes

Ringraziamenti

Si ringraziano la dottoressa Ilaria Cosci e il dottor Alberto Bottacin per aver contribuito alla stesura del testo e all’individuazione della bibliografia di pertinenza.

Conflitto di interesse

Gli autori Andrea Garolla, Andrea Canossa, Marco Ghezzi e Carlo Foresta dichiarano di non avere conflitti di interesse.

Consenso informato

La procedura di crioconservazione è stata adeguatamene spiegata ai pazienti i quali hanno firmato un consenso informato.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Supplementary material

40619_2019_535_MOESM1_ESM.doc (29 kb)
(DOC 29 kB)
40619_2019_535_MOESM2_ESM.doc (32 kb)
(DOC 32 kB)

Bibliografia

  1. 1.
    Znaor A, Lortet-Tieulent J, Jemal A, Bray F (2014) International variations and trends in testicular cancer incidence and mortality. Eur Urol 65:1095–1106 CrossRefGoogle Scholar
  2. 2.
    D’Aniello C, Cavaliere C, Cecere S et al. (2014) Uncommon tumors of the testis. WCRJ 1:e248 Google Scholar
  3. 3.
    Bogefors C, Isaksson S, Bobjer J et al. (2017) Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome. Andrology 5(4):711–717 CrossRefGoogle Scholar
  4. 4.
    Ghezzi M, Berretta M, Bottacin A et al. (2016) Impact of bep or carboplatin chemotherapy on testicular function and sperm nucleus of subjects with testicular germ cell tumor. Front Pharmacol 7:122 CrossRefGoogle Scholar
  5. 5.
    Ghezzi M, De Toni L, Palego P et al. (2017) Increased risk of testis failure in testicular germ cell tumor survivors undergoing radiotherapy. Oncotarget 9(3):3060–3068 Google Scholar
  6. 6.
    Rives N, Walschaerts M, Setif V et al. (2017) Sperm aneuploidy after testicular cancer treatment: data from a prospective multicenter study performed within the French Centre d’Étude et de Conservation des Oeufs et du Sperme network. Fertil Steril 107(3):580–588 CrossRefGoogle Scholar
  7. 7.
    Meistrich ML (2013) Effects of chemotherapy and radiotherapy on spermatogenesis in humans. Fertil Steril 100:1180–1186 CrossRefGoogle Scholar
  8. 8.
    Haugnes HS, Bosl GJ, Boer H et al. (2012) Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. Clin Oncol 30:3752–3763 CrossRefGoogle Scholar
  9. 9.
    Klosky JL, Wang F, Russell KM et al. (2017) Prevalence and predictors of sperm banking in adolescents newly diagnosed with cancer: examination of adolescent, parent and provider factors influencing fertility preservation outcomes. J Clin Oncol 35:1–7 CrossRefGoogle Scholar
  10. 10.
    Ethics Committee of the American Society for Reproductive Medicine (2018) Fertility preservation and reproduction in patients facing gonadotoxic therapies: an ethics committee opinion. Fertil Steril Google Scholar
  11. 11.
    Sadri-Ardekani H, Atala A (2014) Testicular tissue cryopreservation and spermatogonial stem cell transplantation to restore fertility: from bench to bedside. Stem Cell Res Ther 5:68 CrossRefGoogle Scholar
  12. 12.
    Rives N, Perdrix A, Hennebicq S et al. (2012) The semen quality of 1158 men with testicular cancer at the time of cryopreservation: results of the French National CECOS Network. J Androl 33:1394–1401 CrossRefGoogle Scholar
  13. 13.
    Gilbert K, Nangia AK, Dupree JM et al. (2018) Fertility preservation for men with testicular cancer: is sperm cryopreservation cost effective in the era of assisted reproductive technology? Urol Oncol 36(3):92 CrossRefGoogle Scholar
  14. 14.
    WHO (1999) Laboratory Manual for the Examination of Human Semen and Sperm–Cervical Mucus Interaction. Cambridge University Press, Cambridge Google Scholar
  15. 15.
    O’Connell M, McClure N, Lewis SE (2002) The effects of cryopreservation on sperm morphology, motility and mitochondrial function. Hum Reprod 17:704–709 CrossRefGoogle Scholar
  16. 16.
    Woolley DM, Richardson DW (1978) Ultrastructural injury to human spermatozoa after freezing and thawing. J Reprod Fertil 53:389–394 CrossRefGoogle Scholar
  17. 17.
    Borges E Jr., Rossi LM, Locambo de Freitas CV et al. (2007) Fertilization and pregnancy out come after intracytoplasmic injection with fresh or cryopreseved ejaculated spermatozoa. Fertil Steril 87:316–320 CrossRefGoogle Scholar
  18. 18.
    Chovanek M, Abu Zaid M, Hanna N et al. (2017) Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol 28:2670–2679 CrossRefGoogle Scholar
  19. 19.
    Trost LW, Brannigan RE (2012) Oncofertility and the male cancer patient. Curr Treat Options Oncol 13(2):146–160 CrossRefGoogle Scholar
  20. 20.
    Bandak M, Lauritsen J, Joliansen C et al. (2018) Sexual function in a nationwide cohort of 2,260 survivors of testicular cancer after 17 years of follow-up. J Urol 200(4):794–800 CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Andrea Garolla
    • 1
    Email author
  • Andrea Canossa
    • 1
  • Marco Ghezzi
    • 1
  • Carlo Foresta
    • 1
  1. 1.Unità di Andrologia e Medicina della Riproduzione, Dipartimento di MedicinaUniversità degli studi di PadovaPadovaItalia

Personalised recommendations